Dr. Yu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
170 Manning Drive Cb7305
Chapel Hill, NC 27599Phone+1 919-966-1996
Summary
- I am a physician scientist trained in hematology/oncology, clinical pharmacology, and protein science, seeking to engineer novel protein-based immunotherapies for the fight against cancer.
Education & Training
- University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2022 - 2025
- University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2019 - 2022
- University of Washington School of MedicineClass of 2019
- University of WashingtonPh.D., Bioengineering, 2008 - 2015
- California Institute of TechnologyB.S., Chemical Engineering, 2004 - 2008
Awards, Honors, & Recognition
- Fred J. Ansfield, MD, Endowed Young Investigator Award Conquer Cancer Foundation, American Society of Clinical Oncology, 2024
- Alexander Grinstein Endowed Fellowship University of Washington, 2009
- Upper Class Merit Award, Carnation Scholarship California Institute of Technology, 2007-2008
- Join now to see all
Clinical Trials
- Pembrolizumab Plus Y90 Radioembolization in HCC Subjects Start of enrollment: 2017 Mar 28
Publications & Presentations
PubMed
- 301 citationsDe novo design of potent and selective mimics of IL-2 and IL-15Daniel-Adriano Silva, Shawn Yu, Umut Ulge, Jamie B. Spangler, Kevin Jude
Nature. 2019-01-09 - 3 citationsA Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma.Shawn Yu, Menggang Yu, Barry Keane, David M Mauro, Paul R Helft
The Oncologist. 2024-03-04
Abstracts/Posters
- Impact of steroid use among patients with renal cell carcinoma (RCC) who develop immune-related adverse events (irAE)Peter Zang, Karen Resnick, Travis Larsen, Shirley Ye, April Choi, Xiao Yu, Kevin Brady, Varsha Tulpule, Anishka D'souza, and Gino Kim In, Journal of Clinical Oncology, 6/2/2022
- Impact of ethnicity and immune-related adverse events (IRAE) on outcomes for non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitorsKaren Resnick, Peter Zang, Travis Larsen, Shirley Ye, April Choi, Xiao Yu, Kevin Brady, Trevor E Angell, Jacob Stephen Thomas, Jorge J. Nieva, and Gino Kim In, Journal of Clinical Oncology, 6/2/2022
- Venous thromboembolism in patients on check point inhibitorsUpama Giri, Xiao Yu, Karen Resnick, Travis Larsen, and Gino Kim In, Journal of Clinical Oncology, 5/28/2021
Other
- De novo design of potent and selective interleukin mimeticsSilva Manzano, D. A.; Yu, S.; Ulge, U.; Baker, D.; Garcia, K. C.; Spangler, J.; Walkey, C.; Rubio, A. Q.; Weitzner, B., US 11117944 B2
https://lens.org/080-135-637-654-248
9/14/2021
Grant Support
- Young Investigator AwardConquer Cancer, the ASCO Foundation2024–2025
- Multispecific T-cell engagers targeting intracellular cancer-testis antigens in urothelial carcinomaNC TraCS2024–2025
- UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training ProgramNational Institute of General Medical Sciences2023–2024
Research History
- Postdoctoral FellowUNC-Duke Collaborative Clinical Pharmacology T32 Postdoctoral Training Program, Brian Kuhlman and William Kim2023 - 2025
- Postdoctoral FellowUniversity of Washington, David Baker2017 - 2018
Professional Memberships
- Member
- Member
- Society for Immunotherapy of Cancer - SITCMember
- Member
Other Languages
- Chinese (Mandarin), Spanish
Industry Relationships
- Co-Founder, Neoleukin Therapeutics2018 - 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: